Wugen

Drug Discovery · Saint Louis, MO · Founded 2018 · Privately Held (backing)

Developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers. Wugen is based in Saint Louis, MO and was founded in 2018. It is valued at about $215 million as of Oct 2026, set by institutional fund marks, down 12% since its later-stage round in Aug 2025. It has raised $323 million across 2 recorded rounds; the latest was an $115 million Series C in Aug 2025.

PMV mark · valuation
$214.5M
Oct 2026
Since last round
-12%
Aug 2025
Total raised
$323.0M
Last round
Later Stage VC (Series C)
Aug 2025

Who backs Wugen?

13 investors
InvestorType
Fidelity Management & Research CompanyAsset manager
Alexandria Venture InvestmentsOther
Alpha Wave GlobalGrowth equity
Sands CapitalGrowth equity
BioGenerator VenturesVenture capital
Aisling CapitalVenture capital
Abingworth—
ICG—
LYZZ Capital—
Lightchain Capital—
+ 3 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Wugen investors

13 investors are on record for Wugen, including Fidelity Management & Research Company, Alexandria Venture Investments, Alpha Wave Global and Sands Capital. By type, the record holds 2 venture capital firms, 2 growth equity firms and 1 asset manager. The Series C in Aug 2025 drew 4 investors.

Free account
More of Wugen with a free account
  • ·The complete investor list: 13 names
  • ·Watch Wugen: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 13 firms already write checks for companies like Wugen in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View